- Home
- BKU vs BLTE Comparison
BKU vs BLTE Comparison
Compare BKU & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKU
- BLTE
- Stock Information
- Founded
- BKU 2009
- BLTE 2018
- Country
- BKU United States
- BLTE United States
- Employees
- BKU N/A
- BLTE N/A
- Industry
- BKU Savings Institutions
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- BKU Finance
- BLTE Health Care
- Exchange
- BKU Nasdaq
- BLTE Nasdaq
- Market Cap
- BKU 2.7B
- BLTE 2.1B
- IPO Year
- BKU 2011
- BLTE 2022
- Fundamental
- Price
- BKU $39.23
- BLTE $63.65
- Analyst Decision
- BKU Hold
- BLTE Strong Buy
- Analyst Count
- BKU 11
- BLTE 4
- Target Price
- BKU $40.27
- BLTE $89.00
- AVG Volume (30 Days)
- BKU 570.4K
- BLTE 71.4K
- Earning Date
- BKU 01-24-2025
- BLTE 11-12-2024
- Dividend Yield
- BKU 2.93%
- BLTE N/A
- EPS Growth
- BKU N/A
- BLTE N/A
- EPS
- BKU 2.44
- BLTE N/A
- Revenue
- BKU $919,935,000.00
- BLTE N/A
- Revenue This Year
- BKU N/A
- BLTE N/A
- Revenue Next Year
- BKU $7.02
- BLTE N/A
- P/E Ratio
- BKU $16.70
- BLTE N/A
- Revenue Growth
- BKU 3.57
- BLTE N/A
- 52 Week Low
- BKU $24.34
- BLTE $31.01
- 52 Week High
- BKU $44.45
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- BKU 48.35
- BLTE 44.83
- Support Level
- BKU $39.44
- BLTE $60.00
- Resistance Level
- BKU $42.04
- BLTE $76.87
- Average True Range (ATR)
- BKU 0.83
- BLTE 4.60
- MACD
- BKU -0.37
- BLTE -0.74
- Stochastic Oscillator
- BKU 24.56
- BLTE 26.56
About BKU BankUnited Inc.
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located primarily throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.